FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

Core Insights - The U.S. FDA has approved Insmed Incorporated's Brinsupri (brensocatib) as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children aged 12 and older [1][5] - Approximately 500,000 individuals in the U.S. are diagnosed with NCFB, highlighting a significant patient population for this treatment [2] - Clinical trials demonstrated that Brinsupri significantly reduced the annual rate of exacerbations by 21.1% and 19.4% for the 10 mg and 25 mg doses, respectively, compared to placebo [3] - The treatment also met secondary endpoints, including prolonging the time to first exacerbation and increasing the proportion of patients remaining exacerbation-free [4] - The safety profile of Brinsupri was generally consistent across studies, with some increased incidence of gingival and periodontal adverse reactions noted in the WILLOW study [5] - Insmed plans to file for approval in Japan in 2025, with commercial launches anticipated in 2026 pending regulatory approvals [5] - Following the FDA approval, Insmed's stock price increased by 6.20% to $119.89 [6]